Thanks Titus.This part, in particular, helps shed further light...

Thanks Titus.

This part, in particular, helps shed further light on the issues:

BARDA director Dr Robin Robinson told Biotech Daily today that “with the challenges this
development project encountered, we felt it was in the best interest of the taxpayer to
support development of other promising influenza antiviral drugs already in our antiviral
drug portfolio and possibly new drugs to treat critically ill patients with influenza”.
“During a recent review, we shared our concerns with the company, including the number
of people enrolled so far in Biota’s phase II clinical trials to evaluate laninamivir in adults
during the recent influenza season; the cost of additional clinical trials; emergence of
resistance to laninamivir in recent H7N9 virus strains; and feasibility using of laninamivir to
treat of critically ill, hospitalized patients with influenza,” Dr Robinson said.